DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 33,359 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

DexCom Stock Performance

DXCM opened at $87.62 on Friday. The company has a market cap of $34.22 billion, a price-to-earnings ratio of 52.47, a PEG ratio of 2.23 and a beta of 1.12. The firm’s fifty day simple moving average is $80.22 and its two-hundred day simple moving average is $76.59. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DXCM shares. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Wells Fargo & Company raised their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Hedge Funds Weigh In On DexCom

Hedge funds have recently made changes to their positions in the company. Jennison Associates LLC lifted its holdings in DexCom by 1,683.2% in the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. raised its holdings in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares during the last quarter. Finally, Intech Investment Management LLC boosted its stake in DexCom by 2,083.0% during the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after buying an additional 369,587 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.